Cervical cancer has emerged as the fastest-growing cancer in Canada, presenting a serious yet often overlooked public health challenge. At a press conference held on Wednesday in Ottawa, the Society of Gynecologic Oncology of Canada urged the federal government to intensify efforts to combat this alarming trend. Their message comes in the wake of Canada’s commitment, laid out in a July 2025 action plan, to eradicate cervical cancer as a public health issue by 2040. However, experts argue that current measures are insufficient.
A Silent Epidemic
Dr. Shannon Salvador, president of the Society of Gynecologic Oncology of Canada, described the situation as a “silent national health crisis.” She highlighted that in 2025 alone, approximately 1,650 Canadians received a cervical cancer diagnosis, with around 430 expected to succumb to the disease—an outcome that could largely be prevented.
“Canada is facing an alarming outlier in cancer rates,” Dr. Salvador remarked, indicating that while advancements in medical science have been celebrated, the responses from health policies have lagged significantly.
The Shortcomings of Current Strategies
Despite Canada’s historical reliance on Pap testing and a strong initial reception to the HPV vaccine introduced in the mid-2000s, the current vaccination rate has stagnated at a mere 64 per cent. “This figure is not just a medical failure; it is a glaring policy failure,” Dr. Salvador asserted, underscoring the critical need for immediate reform.
In response to these shortcomings, the Society is advocating for a national shift towards HPV DNA testing for cervical cancer screening. This new screening method, combined with the introduction of self-collection kits, aims to enhance accessibility and encourage more individuals to participate in screening.
Innovative Solutions for Better Access
The Canadian Cancer Society has outlined that HPV testing can be conducted using swabs to collect samples either from the cervix or the vagina. The introduction of self-administered kits is a crucial step in removing barriers to screening, particularly for those who face challenges such as geographic isolation, trauma history, or inadequate access to healthcare providers.
Dr. Sarah Kean, the provincial lead for cervical cancer in Manitoba, highlighted that Indigenous women, who experience disproportionately higher rates of cervical cancer, are often confronted with systemic barriers. “It is not biology that accounts for these disparities but rather the lack of accessible resources, geographic isolation, systemic racism, and the lingering impacts of colonial practices,” she explained.
A Call for Comprehensive Legislative Support
Dr. Kean emphasised the necessity for robust and accessible HPV screening programmes across Canada, advocating for supportive federal legislation. “Comprehensive HPV screening must extend beyond mere updates to guidelines; it should guarantee universal access to primary HPV testing across all provinces and territories with established national standards,” she stated.
In 2024, the financial burden of treating cervical cancer on the Canadian healthcare system was estimated at a staggering £132 million, while screening eligible Canadians would cost around £106 million over five years. Such figures illustrate the pressing need for effective preventative measures.
Why it Matters
Cervical cancer remains one of the most preventable forms of cancer, yet the stagnation of vaccination rates and inadequate screening policies are contributing to its rise in Canada. The urgent call from health experts for a national shift in screening practices and legislative action highlights a critical moment for public health. With the right policies and support in place, Canada has the potential to significantly reduce cervical cancer incidences and improve health outcomes for countless individuals, particularly those in vulnerable communities. Addressing this crisis is not merely a matter of healthcare—it is a moral imperative that requires immediate action.
